Research programme: beta-catenin responsive transcription inhibitors - ibeCa Thearpeutics
Latest Information Update: 29 Mar 2016
At a glance
- Originator New York University School of Medicine
- Class Antineoplastics; Oxazoles; Small molecules; Thiazoles
- Mechanism of Action Beta catenin inhibitors; Transcription factor inhibitors; Wnt signalling pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer